MOG35‐55 I.v Suppress Experimental Autoimmune Encephalomyelitis Through Modulation of Pro‐Inflammatory Cytokines and JAK/Stats Pathway

Hongmei Li,Zhilong Jiang,Guang Xian Zhang,Denise C. Fitzgerald,Abdolmohamad Rostami

DOI: https://doi.org/10.1096/fasebj.22.2_supplement.399

2009-01-01

European Journal of Immunology

Abstract:Intravenous (i.v.) administration of encephalitogenic peptide can effectively prevent experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis, while the underlying cellular and molecular mechanisms are not fully investigated. In this study, we induced i.v. tolerance against EAE by administration of MOG35‐55 peptide and determined the effect of this approach on intracellular signaling pathways for IL‐23/IL‐17 system, which is essential for the pathogenesis of MS/EAE. In EAE mice, phosphorylation of Janus kinase/signal transducer and activator of transcription (STAT)‐1, −4, ERK1/2 and NF‐κBp65 were highly elevated in splenocytes and infiltrating lymphocytes of spinal cords, whereas their activation were significantly inhibited in MOG‐i.v. mice. IL‐17 expression was suppressed in MOG i.v. tolerant mice, and administration of exogenous IL‐17 partially broke immune tolerance by reverse activation of STAT4. The suppressed STAT4 phosphorylation and NF‐κB activation were mostly located in CD11b+ splenocytes cells; adoptive transfer of CD11b+ splenocytes cells from tolerogenic mice effectively delayed onset and reduced clinical severity of EAE. In addition, MOG i.v. treatment led to higher expression of IL‐10, IL‐12, and IL‐27 in ex vivo splenocytes than in EAE control mice. Recombinant IL‐12 and IL‐27 suppressed IL‐17 expression in vitro, consistent with the regulatory function of IL‐12 and IL‐27 in MOG i.v. induced tolerance. This study defined the correlation of MOG i.v. tolerance with multiple pro‐inflammatory signaling pathways and provided novel therapeutic targets for the treatment of EAE/MS.